Showing results (1721-1730 of 1,799) with videos related to

Sort By:
Pageof 180
Nature Genetics|April 24, 2012
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndromeTobias Willer, Hane Lee, Mark Lommel, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.
Transplantation and Cellular Therapy|July 19, 2022
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell LymphomasPeter A Riedell, Wei-Ting Hwang, Loretta J Nastoupil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Neurodevelopmental Disorders|October 26, 2016
Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variationMatthew J Gazzellone, Mehdi Zarrei, Christie L Burton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Cell Reports|August 2, 2025
Plasma extracellular vesicle surface-located GAS6/PROS1 and CD39/CD73 attenuate inflammationMartina P Fabiano, Alan M Adamczyk, Olesia A Gololobova, et al.
Pageof 180